SCA7

1

Review clinical trials related to SCA7. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.

Participants needed: 34
Trial details
Phase: Phase 2, Phase 3Age: 7+Biological sex: AllType: InterventionalSponsor: S. Andrea HospitalUpdated: Dec 2, 2024Locations: 1
Eligibility criteria

positive genetic test for SCA7.

cardiac arrhythmias; [+4]